You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明系受捧 升逾4%-7%
藥明系今早受捧,尤其是藥明合聯(02268.HK)續升7.1%報19.04元。藍籌藥明生物(02269.HK)及藥明康德(02359.HK)重越20天線,最高見19.28元及51.45元,現報19元及50.35元,均回升逾4%。 其餘醫藥股以來凱醫藥-B(02105.HK)表現較好,曾高見3.95元,現報3.71元,回升7.1%。騰盛博藥-B(02137.HK)回升5%報1.89元。 君實生物(01877.HK)、康寧傑瑞製藥-B(09966.HK)、凱萊英(06821.HK)、康希諾生物(06185.HK)、康龍化成(03759.HK)升逾2%-4%,後者升幅最大,報10.82元,回升4.6%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account